Selective serotonin reuptake inhibitors (SSRIs) taken by a woman during pregnancy do not impact her infant's growth during the first year of life, reports a new small study.
Selective serotonin reuptake inhibitors (SSRIs) taken by a woman during pregnancy do not impact her infant's growth during the first year of life, reports a new small study.
The study, published March 20, 2013, on the website of The American Journal of Psychiatry, shows that infants born to mothers who took SSRIs had similar weights, lengths, and head circumferences over the course of their first year as infants born to women who did not take SSRIs.
For the study, pregnant women were evaluated at weeks 20, 30, and 36 of gestation, and mother-and-infant pairs were assessed at 2, 12, 26, and 52 weeks postpartum. Three nonoverlapping groups of women were defined according to their pregnancy exposures: 1) no SSRI and no depression (N=97), 2) SSRI (N=46), and 3) major depression without SSRI (N=31). Maternal demographic and clinical characteristics and newborn outcomes were compared among exposure groups. Infant weight, length, and head circumference were measured by a physician or physician assistant who was blind to depression and SSRI exposure status at each postpartum time point.
The researchers found that neither antenatal major depression nor SSRI exposure was significantly associated with infant weight, length, or head circumference. In addition, the researchers noted, the interaction of group and prepregnancy body mass index was evaluated, and no significant synergistic effect was identified.
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
How genetic variables impact oral contraceptive use and VTE risk
March 27th 2024A comprehensive study delved into the interplay of polygenic and hereditary factors in venous thromboembolism risk among oral contraceptive users, shedding light on potential genetic markers for refined risk assessment and counseling.
Read More
FDA grants FTD to nipocalimab for treating FNAIT
March 26th 2024The FDA's Fast Track Designation for nipocalimab marks a significant step in addressing fetal neonatal alloimmune thrombocytopenia risk in pregnant patients, potentially revolutionizing treatment for this severe condition with unmet medical needs.
Read More
Study links low neighborhood food access to adverse birth outcomes
March 26th 2024A recent study highlighted the link between residence in low-income areas with limited food access during pregnancy and increased risks of lower birth weight and small for gestational age infants, urging further investigation into potential interventions for improved birth outcomes.
Read More